NH · NSE
Narayana Hrudayalaya Ltd.
₹1,943.7
+3.77% (+₹70.6)
Prev. close
₹1,873.1
Volume
7,84,702
Delivery %
29.1%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Prabhudas Lilladher recommends buying Narayana Hrudayalaya with a target price of ₹2,100. The call implies a bullish out…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Narayana Hrudayalaya | MISS | |
| “Choice Institutional Equities recommends buying Narayana Hrudayalaya with a target price of ₹2,500. The call implies a b…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Narayana Hrudayalaya Ltd | MISS | |
| “Bullish on Narayana Hrudayalaya, projecting 13.9% YoY revenue growth in Q2FY26, driven by higher ARPOB and the ramp-up o…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Narayana Hrudayalaya Ltd | MISS | |
| “Prabhudas Lilladher recommends buying Narayana Hrudayalaya with a target price of ₹1950. The call is based on the compan…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Narayana Hrudayalaya Ltd. | HIT | |
| “Bullish on Narayana Hrudayalaya with a target of ₹1,880 and a stop loss at ₹1,800, recommending a buy for short-term tra…” | Kunal BothraIndependent | Narayana Hrudayalaya | MISS | |
| “Bullish on Narayana Hrudayalaya for the next three months. Recommends buying above ₹1,680 or on dips to ₹1,600, with a s…” | Raja VenkatramanNeoTrader | Narayana Hrudayalaya Ltd | HIT | |
| “Recommends buying Narayana Hrudayalaya with a target of ₹1,785 and a stop loss at ₹1,513, indicating a short-term bullis…” | Rajesh PalviyaAxis Securities | Narayana Hrudayalaya | HIT | |
| “Anand Rathi recommends buying Narayana Hrudayalaya Ltd. in the range of Rs 1400-1440, with a target price of Rs 1600 and…” | Anand Rathi AnalysisAnand Rathi | Narayana Hrudayalaya Ltd. | PENDING | |
| “Recommends buying Narayana Hrudayalaya at ₹1491 with a target of ₹1580 and a stop loss at ₹1440, based on strong technic…” | Sumeet BagadiaChoice Equity Broking | Narayana Hrudayalaya Ltd | HIT | |
| “Bullish on Narayana Hrudayalaya, recommending a buy in the range of ₹1,400 to ₹1,440 with a target price of ₹1,600 and a…” | Anand Rathi AnalysisAnand Rathi | Narayana Hrudayalaya | PENDING | |
| “Bullish on Narayana Hrudayalaya for the long term, with a target price of ₹1,600. The company's revenues grew nearly 14%…” | Pankaj PandeyICICI Securities | Narayana Hrudayalaya Ltd | PENDING | |
| “Recommends buying Narayana Hrudayalaya with a target price of ₹1550. The call implies a bullish outlook on the stock.” | Anand Rathi AnalysisAnand Rathi | Narayana Hrudayalaya | PENDING | |
| “Recommends buying Narayana Hrudayalaya with a target price of ₹1560. The call implies a bullish outlook on the stock.” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Narayana Hrudayalaya | PENDING | |
| “Recommends buying Narayana Hrudayalaya today at ₹1370.1, targeting ₹1460, with a stop loss at ₹1320, based on strong tec…” | Sumeet BagadiaChoice Equity Broking | Narayana Hrudayalaya | HIT | |
| “Bullish on Narayana Hrudayalaya Ltd with a buy range of ₹1,340-1,380, targeting ₹1,630 with a stop loss at ₹1,250 over a…” | Marketsmith India AnalysisMarketsmith India | Narayana Hrudayalaya Ltd | PENDING | |
| “Bullish on Narayana Hrudayalaya, identifying it as a top pick in the healthcare space due to its significant capex plans…” | Pankaj PandeyICICIdirect.com | Narayana Hrudayalaya Ltd. | HIT | |
| “Bullish on Narayana Hrudayalaya with a target of ₹1595 and a stop loss at ₹1331, suitable for traders with a short-term …” | Aakash HindochaNuvama Professional Clients Group | Narayana Hrudayalaya | MISS | |
| “Choice Institutional Equities recommends buying Narayana Hruduyalaya with a target price of ₹1,405, based on a positive …” | Choice Institutional Equities AnalysisChoice Institutional Equities | Narayana Hrudayalaya Ltd | PENDING | |
| “Recommends buying Narayana Hrudayalaya Ltd with a target of ₹1350 and a stop loss at ₹1268 for a short-term trading hori…” | Kunal BothraIndependent | Narayana Hrudayalaya Ltd | HIT | |
| “Bullish on Narayana Hrudayalaya Ltd, recommending a buy at ₹1,331 with a target of ₹1,400 and a stop loss at ₹1,290, for…” | Nagaraj ShettiHDFC Securities | Narayana Hrudayalaya Ltd | MISS | |
| “Recommends buying Narayana Hrudayalaya with a target price of ₹1550. The call implies a bullish outlook on the stock.” | Anand Rathi AnalysisAnand Rathi | Narayana Hrudayalaya Ltd | PENDING |
Market commentary · 6 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Narayana Hrudayalaya, having added to the position over the last 12 months. This aligns with his positive out…” | Saurabh MukherjeaMarcellus Investment Managers | Narayana Hrudayalaya | — | |
| “Bullish on Narayana Hrudayalaya Ltd, recommending a buy in the range of ₹1,340-1,380 with a profit goal of ₹1,630 and a …” | Marketsmith India AnalysisMarketsmith India | Narayana Hrudayalaya Ltd | — | |
| “Recommends buying Narayana Hrudayalaya Ltd within the range of ₹1,340-1,380, targeting a profit goal of ₹1,630 with a st…” | Marketsmith India AnalysisMarketsmith India | Narayana Hrudayalaya Ltd | — | |
| “Maintains a 'Hold' rating on Narayana Hrudayalaya with a target price of Rs 1,460, valuing it at an EV/EBITDA of 18x on …” | Choice Institutional Equities AnalysisChoice Institutional Equities | Narayana Hrudayalaya Ltd | — | |
| “Bullish on Narayana Hrudayalaya Ltd, recommending a buy in the range of ₹1,340–1,380 with a profit goal of ₹1,630 and a …” | Marketsmith India AnalysisMarketsmith India | Narayana Hrudayalaya Ltd | — | |
| “Recommends Narayana Hrudayalaya Ltd. with a buy range of ₹1,340-1,380, targeting a profit goal of ₹1,630 within 2-3 week…” | Marketsmith India AnalysisMarketsmith India | Narayana Hrudayalaya Ltd. | — |
Fundamentals
About Narayana Hrudayalaya Ltd.
Narayana Hrudayalaya Limited provides medical and healthcare services in India, the United Kingdom, and the Cayman Islands. It operates through the Medical and Healthcare Related Services; and Others segments. The company offers oncology, anesthesiology, audiology, blood bank, breast oncology, oncoplastic surgery, cardiac surgery, cardiology, clinical genetics, clinical immunology, clinical nutrition and dietetics, clinical psychology, congenital adult heart disease, cosmetology, cranio-maxillofacial surgery, critical care medicine, dental, dermatology, diabetology, ENT, emergency medicine, endocrinology, family medicine, general and GI surgery, general medicine and surgery, geriatric medicine, gynecology, hematology, headache and facial pain management, transplant, infectious diseases, neurology, radiology, hepatobiliary surgery, gastroenterology, minimal access GI and bariatric surgery, neonatology, nephrology, neuro-otology, neuro-rehabilitation, neurosurgery and spine surgery, and nuclear medicine services. It also provides ophthalmology, orthopedics and joint replacement, pain management and palliative care, pathology, perinatology and fetal intervention, physical medicine and rehabilitation, physiotherapy and physical rehabilitation, plastic surgery, psychiatry, pulmonology, reproductive medicine, rheumatology, renal science, speech and swallow rehabilitation, spine surgery, thoracic and vascular surgery, uro oncology, urology, and other services. In addition, the company acquires, owns, and operates hospitals, clinics, health centers, diagnostic centers, and nursing homes. Further, it provides health insurance, consultancy services in the field of healthcare and hospitals, and IT services related to healthcare. Additionally, the company engages in investment activities; and develops software related to the healthcare industry. The company was incorporated in 2000 and is headquartered in Bengaluru, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Emmanuel Rupert
Headquarters
Bengaluru
Employees
11,234
Website
narayanahealth.orgExchange
View on NSE ↗Key stats
Market cap
₹39,401.37 Cr
P/E ratio (TTM)
44.2
Dividend yield
0.23%
EPS (TTM)
₹43.92
Beta (1Y · daily vs NIFTY 50)
0.85
Beta (5Y · monthly vs NIFTY 50)
0.94
Shares float
6.60 Cr
EPS · quarter ended Sept 2026
₹14.82
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,582.35 Cr | ₹3,701.32 Cr | ₹4,524.77 Cr | ₹5,018.25 Cr | ₹5,482.98 Cr | ₹7,896.04 Cr | |
EBITDA | ₹203.44 Cr | ₹679.56 Cr | ₹1,031.08 Cr | ₹1,227.55 Cr | ₹1,360.06 Cr | ₹1,665.94 Cr |
| ₹-14.30 Cr | ₹341.93 Cr | ₹606.25 Cr | ₹789.26 Cr | ₹790.16 Cr | ₹805.60 Cr | |
Diluted EPS | ₹-0.7 | ₹16.84 | ₹29.85 | ₹38.86 | ₹38.9 | ₹39.67 |
EBITDA for Mar 2021 could not be checked against the company's own annual report: this page shows ₹203.44 Cr while the annual report gives ₹210.28 Cr (3.4% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹446.67 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,770.02 Cr | ₹3,130.53 Cr | ₹4,162.09 Cr | ₹5,624.58 Cr | ₹7,265.03 Cr | ₹12,474.40 Cr | |
| ₹825.64 Cr | ₹723.42 Cr | ₹884.17 Cr | ₹1,626.69 Cr | ₹2,428.37 Cr | ₹5,857.50 Cr | |
Stockholders' equity | ₹1,120.28 Cr | ₹1,488.64 Cr | ₹2,131.38 Cr | ₹2,883.68 Cr | ₹3,626.36 Cr | ₹4,537.26 Cr |
Trade receivables, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹309.05 Cr | ₹485.02 Cr | ₹1,084.56 Cr | ₹1,066.60 Cr | ₹990.08 Cr | ₹1,618.46 Cr | |
Investing cash flow | ₹-112.99 Cr | ₹-266.91 Cr | ₹-1,174.10 Cr | ₹-1,457.94 Cr | ₹-1,317.12 Cr | ₹-3,699.90 Cr |
| ₹-198.43 Cr | ₹-158.95 Cr | ₹87.74 Cr | ₹488.45 Cr | ₹544.31 Cr | ₹2,342.93 Cr | |
Capital expenditure | ₹-70.10 Cr | ₹-250.68 Cr | ₹-522.04 Cr | ₹-970.61 Cr | ₹-1,073.76 Cr | ₹-874.94 Cr |
End cash position | ₹89.51 Cr | ₹148.53 Cr | ₹144.59 Cr | ₹241.74 Cr | ₹447.16 Cr | ₹760.57 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Mar 22(3Q) | Jun 22–Sep 22(2Q) | Dec 22–Jun 23(3Q) | Sep 23–Sep 25(9Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|---|---|
| Promoter | 63.85% | 63.85% | 63.85% | 63.85% | 63.27% |
| Public | 35.45% | 35.46% | 35.52% | 35.53% | 36.11% |
| Employee trusts | 0.70% | 0.69% | 0.63% | 0.62% | 0.62% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Narayana Hrudayalaya Ltd. | ₹38,814.41 Cr | ₹1,931.5 | 44.9 | 8.55 | 17.8% | 1.29 | +43.8% | +5.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.